Investing.com - Proteostasis Therapeutics (NASDAQ:YMTX) reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Proteostasis Therapeutics announced earnings per share of $-0.31 on revenue of $1.4M. Analysts polled by Investing.com anticipated EPS of $-1.08 on revenue of $2.5M.
Proteostasis Therapeutics shares are down 67% from the beginning of the year, still down 67.26% from its 52 week high of $5.34 set on November 15, 2021.
Proteostasis Therapeutics follows other major Healthcare sector earnings this month
Proteostasis Therapeutics's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar